Lawyer Profile
Melissa M. Dimilta
Toronto, Ontario
Overview
Melissa, the Firm's Intellectual Property, National Practice Group Leader, practices in all areas of intellectual property law, assisting clients across a broad spectrum of industries—including pharmaceuticals, biotechnology, food, medical devices, consumer products, agriculture, retail, and luxury goods—with a particular emphasis on Health Canada regulated sectors.
Melissa has extensive experience resolving and litigating intellectual property disputes, with a focus on patent and trademark litigation. She is recognized for her significant expertise in proceedings under the Patented Medicines (Notice of Compliance) Regulations and has represented clients before the Federal Court, Federal Court of Appeal, the Ontario Courts, as well as the Trademarks Opposition Board.
Melissa’s practice includes advising clients on all aspects of intellectual property law, including patent, trademark, copyright, and industrial design matters. She is deeply involved in trademark prosecution and opposition proceedings, and provides strategic guidance on portfolio management, commercialization, and enforcement of intellectual property rights.
She is a member of the Advocates' Society, the Intellectual Property Institute of Canada, and the Canadian Bar Association.
Amgen Canada Inc. in the first motion to delist a patent under the new Patented Medicines (Notice of Compliance Regulations) (Bayer Inc v Amgen Canada Inc, 2024 FC 1849)
Amgen Canada Inc. in a judicial review application brought by Bayer Inc. (Bayer Inc. v Amgen Canada Inc., 2025 FC 107 aff'd 2025 FCA 142)
Amgen Canada Inc. on a motion to compel samples brought by Bayer Inc. and Regeneron Pharmaceuticals Inc. (2025 FC 264)
Amgen Canada Inc. in five different actions brought by Bayer Inc. and Regeneron Pharmaceuticals Inc. under the Patented Medicines (Notice of Compliance Regulations) related to the drug aflibercept
Practice Areas
Bar Information
Called to the bar: 2012 (ON)